MAXWELL FINLAND, M.D., F.A.C.P.; HARVEY SHIELDS COLLINS, M.D.; THOMAS M. GOCKE, M.D.; E. BUIST WELLS, M.D.
Aureomycin is the most recent antibiotic to be accepted into the group of antimicrobial agents that are highly effective in the therapy of human infections. The activity of this antibiotic seems to extend over a wider range of infectious agents than that of any of its predecessors. It is effective when given by mouth and has thus far been found to be essentially free of serious untoward effects. The exact field of usefulness of aureomycin, however, still remains to be defined and it will be necessary to accumulate a considerably greater body of well controlled clinical data than are as
MAXWELL FINLAND, HARVEY SHIELDS COLLINS, THOMAS M. GOCKE, E. BUIST WELLS. PRESENT STATUS OF AUREOMYCIN THERAPY(PRESENT STATUS OF AUREOMYCIN THERAPY*). Ann Intern Med. 1949;31:39–52. doi: 10.7326/0003-4819-31-1-39
Download citation file:
Published: Ann Intern Med. 1949;31(1):39-52.
Education and Training, Infectious Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use